Celgene Corp (CELG) 114.69 $CELG
Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.45% Rise
Comtex SmarTrend(R) - Mon Aug 01, 12:02PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $111.61 to a high of $115.02. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $112.43 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)
Company News for July 29, 2016
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:10AM CDT
Companies In The News are: CELG,MA,HOG,AMGN
HOG: 51.66 (-1.26), AMGN: 174.16 (+2.13), MA: 95.07 (-0.17), CELG: 114.69 (+2.50)
Celgene Rises 2.40% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jul 28, 11:52AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.80 to a high of $111.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $108.84 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 2.40% Gain
Comtex SmarTrend(R) - Thu Jul 28, 11:50AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.80 to a high of $111.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $108.84 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)
Celgene (CELG) Tops Q2 Earnings & Revenues, Lifts View
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 11:11AM CDT
Celgene (CELG) reported better-than-expected second-quarter 2016 earnings and revenues; it once again raised the earnings outlook for 2016.
INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), CELG: 114.69 (+2.50)
Watch for Shares of Celgene (CELG) to Approach Resistance at $110.78
Comtex SmarTrend(R) - Thu Jul 28, 8:34AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $107.50 today and has reached the first level of resistance at $109.45. Analysts will be watching for a cross of the next upside pivot targets of $110.78 and $114.06.
CELG: 114.69 (+2.50)
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)
Celgene (CELG) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:17AM CDT
Celgene beat on second-quarter 2016 earnings and revenues.
CELG: 114.69 (+2.50)
Celgene Reports Second Quarter 2016 Operating and Financial Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--- REVLIMID(R) Net Product Sales $1.7B in Q2:16; Increased 18% Y/Y
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)
Celgene and LYSARC Provide Update on the Phase III 'REMARC' Study of REVLIMID(R) Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy
BusinessWire - Mon Jul 25, 3:30PM CDT
Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial data from a phase III, randomized, double-blind, international clinical study (REMARC). This investigational study evaluated maintenance therapy with REVLIMID(R) (lenalidomide) compared with placebo in diffuse large B-cell lymphoma (DLBCL) patients responding to first-line rituximab plus CHOP chemotherapy (R-CHOP) induction therapy. LYSARC sponsored the study under a Clinical Trial Agreement with Celgene.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:45PM CDT
Celgene's (CELG) Revlimid gained label expansion in the EU; it can now be used for the treatment of adults with relapsed or refractory mantle cell lymphoma.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), CELG: 114.69 (+2.50)
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
BusinessWire - Fri Jul 15, 1:00AM CDT
--Approval gives Celgene its first opportunity to support unmet needs of lymphoma patients across the European Union
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
InvestorsObserver releases covered-call reports for Freeport-McMoRan, Intel, Agrium Incorporated, Caterpillar Inc. and Celgene
PR Newswire - Thu Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AGU, CAT, CELG, FCX, and INTC.
FCX: 12.48 (-0.48), AGU: 90.09 (-0.67), CAT: 81.95 (-0.81), INTC: 34.85 (-0.01), CELG: 114.69 (+2.50)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 64.08 (+0.09), BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), UNH: 143.51 (+0.31), MRK: 58.66 (unch), ALXN: 133.50 (+4.90), XOM: 85.86 (-3.09), CVX: 99.11 (-3.37), REGN: 434.00 (+8.88), CELG: 114.69 (+2.50)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.35 (+0.03), ARIA: 9.71 (+0.20), CELG: 114.69 (+2.50), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02)
Watch for Celgene to Potentially Pullback After Gaining 3.49% Yesterday
Comtex SmarTrend(R) - Wed Jul 06, 11:56AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $100.13 to a high of $104.94. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $101.39 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)
Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.45% Rise
Comtex SmarTrend(R) - Mon Aug 01, 12:02PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $111.61 to a high of $115.02. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $112.43 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)
Company News for July 29, 2016
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:10AM CDT
Companies In The News are: CELG,MA,HOG,AMGN
HOG: 51.66 (-1.26), AMGN: 174.16 (+2.13), MA: 95.07 (-0.17), CELG: 114.69 (+2.50)
Celgene Rises 2.40% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jul 28, 11:52AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.80 to a high of $111.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $108.84 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 2.40% Gain
Comtex SmarTrend(R) - Thu Jul 28, 11:50AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.80 to a high of $111.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $108.84 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)
Celgene (CELG) Tops Q2 Earnings & Revenues, Lifts View
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 11:11AM CDT
Celgene (CELG) reported better-than-expected second-quarter 2016 earnings and revenues; it once again raised the earnings outlook for 2016.
INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), CELG: 114.69 (+2.50)
Watch for Shares of Celgene (CELG) to Approach Resistance at $110.78
Comtex SmarTrend(R) - Thu Jul 28, 8:34AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $107.50 today and has reached the first level of resistance at $109.45. Analysts will be watching for a cross of the next upside pivot targets of $110.78 and $114.06.
CELG: 114.69 (+2.50)
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)
Celgene (CELG) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:17AM CDT
Celgene beat on second-quarter 2016 earnings and revenues.
CELG: 114.69 (+2.50)
Celgene Reports Second Quarter 2016 Operating and Financial Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--- REVLIMID(R) Net Product Sales $1.7B in Q2:16; Increased 18% Y/Y
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)
Celgene and LYSARC Provide Update on the Phase III 'REMARC' Study of REVLIMID(R) Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy
BusinessWire - Mon Jul 25, 3:30PM CDT
Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial data from a phase III, randomized, double-blind, international clinical study (REMARC). This investigational study evaluated maintenance therapy with REVLIMID(R) (lenalidomide) compared with placebo in diffuse large B-cell lymphoma (DLBCL) patients responding to first-line rituximab plus CHOP chemotherapy (R-CHOP) induction therapy. LYSARC sponsored the study under a Clinical Trial Agreement with Celgene.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:45PM CDT
Celgene's (CELG) Revlimid gained label expansion in the EU; it can now be used for the treatment of adults with relapsed or refractory mantle cell lymphoma.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), CELG: 114.69 (+2.50)
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
BusinessWire - Fri Jul 15, 1:00AM CDT
--Approval gives Celgene its first opportunity to support unmet needs of lymphoma patients across the European Union
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
InvestorsObserver releases covered-call reports for Freeport-McMoRan, Intel, Agrium Incorporated, Caterpillar Inc. and Celgene
PR Newswire - Thu Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AGU, CAT, CELG, FCX, and INTC.
FCX: 12.48 (-0.48), AGU: 90.09 (-0.67), CAT: 81.95 (-0.81), INTC: 34.85 (-0.01), CELG: 114.69 (+2.50)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 64.08 (+0.09), BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), UNH: 143.51 (+0.31), MRK: 58.66 (unch), ALXN: 133.50 (+4.90), XOM: 85.86 (-3.09), CVX: 99.11 (-3.37), REGN: 434.00 (+8.88), CELG: 114.69 (+2.50)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.35 (+0.03), ARIA: 9.71 (+0.20), CELG: 114.69 (+2.50), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02)
Watch for Celgene to Potentially Pullback After Gaining 3.49% Yesterday
Comtex SmarTrend(R) - Wed Jul 06, 11:56AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $100.13 to a high of $104.94. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $101.39 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)
